Market Reports

Enhancing clinical trial supply with JTM: part II

In a constantly changing world, the pharmaceutical industry is having to adopt its practices to serve the needs of a rapidly growing and ageing population and develop innovative personalised medicines. Almac has responded to these demands with a Just-in-Time Manufacturing solution that fulfils the requirements of a high value, time sensitive clinical supply chain. Dr Kevin Robinson spoke to Natalie Balanovsky, Just-in-Time Manufacturing Solutions Manager, and Mark Rohlfing, Vice President of Operations, to find out more

Next-generation pharmaceutical spray drying

Lonza's Kimberly B. Shepard, Associate Principal Engineer, and Michael M. Morgen, Associate Director, R&D, discuss mechanistic process development with high-performance polymers for bioavailability enhancement

Reading and understanding vendor-supplied tablet drawings

Understanding the tablet drawings supplied by tooling vendors is a meaningful way to learn more about your product, reports John Norman, Technical Service Representative, Natoli Engineering Company

Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain

The pharmaceutical industry has responded extremely well to the coronavirus pandemic. At the same time, the industry is changing before our eyes. To put it in simple terms, there will be no more “business-as-usual” in pharmaceutical manufacturing after COVID-19, explains Andrew Badrot, CEO, C2 PHARMA

A pivotal time for pharma's global biotechnology industry

In these uncertain times, GEA, the globally active mechanical and plant engineering company, is taking its role in the fight against the coronavirus — and any other — epidemic, extremely seriously. Committed to “Engineering for a better world,” GEA designs and builds modular plant and fully integrated systems help to bring new treatments to market in the shortest possible time

Accelerating vaccine development with AI

Despite the tremendous advances in medical science in recent decades, there is still so much about the human body that we’re yet to discover, reports Billy Sisk, Life Sciences Industry Manager, EMEA, Rockwell Automation

How to comply with FDA-imposed nitrosamine impurity testing

The detection of nitrosamine impurities in commercially available drugs has recently prompted the US FDA to issue multiple product recalls and mandate additional testing to safeguard consumer health and safety; Michael Walker, Technical Expert at Intertek Pharmaceutical Services, and Jon Bardsley, Vertical Marketing Specialist, Pharma and BioPharma, Thermo Fisher Scientific, report

Excipient innovation for enhanced patient compliance: part II

Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing

Future-proof DMPK studies for next-generation therapeutics

SCIEX's Lei Xiong, Rolf Kern and Elliott Jones explain the top five reasons why you can’t count on ligand-binding assays to study the drug metabolism and pharmacokinetics of biologics

Tackling coronavirus with AI-derived combination drug products: Part I

The ongoing spread of COVID-19 is risking the lives of millions of rare disease patients around the world. Dr David Brown, Chairman and cofounder of Healx, believes the company’s data-driven AI platform is perfectly positioned to support the efforts to find effective treatments and, within weeks, predict which known drugs can be repurposed to treat other conditions

New date announced for Manufacturing Chemist Live

The inaugural conference will now take place on 28-29 October 2020

Excipient innovation for enhanced patient compliance: part I

Formulation can be challenging, particularly when working with excipients such as sugar alcohols. However, a new line extension from SPI Pharma offers a solution that leverages the patient-centric benefits of mannitol while avoiding common drug development problems and simplifying manufacturing

Sustainability and innovation in the complex combination therapy sector

The patient and commercial benefits of bringing new drugs to market in the shortest possible time are well recognised; potential methodologies to reduce the development cycle and accelerate drug product approvals are constantly being explored. As a result, other targets, including the environmental efficacy of a therapy, have traditionally been a distant, secondary objective. Bespak's Jay Bhogaita, Business Director, reports

Delivering certainty in uncertain times

Contract manufacturing organisations (CMOs) in the pharmaceutical sector operate at the sharp end of an industry in which one mistake or delay could be serious or even fatal. Rodney Steel, CEO of the British Contract Manufacturers and Packers Association (BCMPA), discovers how CMOs have become experts in predicting the future, ensuring that nothing is left to chance

Service in times of bits and bytes

Whoever talks to the service experts at Syntegon Technology, formerly Bosch Packaging Technology, communicates both digitally and globally. The shift from analogue to bits and bytes has not only changed communication between service employees and customers. In the course of digitisation, the company has modernised and expanded its entire service portfolio — and has reinvented itself to a certain extent

How AI will disrupt drug development

In the last 4–6 years, companies have been experimenting with new approaches that utilise the latest in artificial intelligence (AI) and machine learning technologies to identify new molecules and validate new drugs faster and more efficiently. Egor Kobelev, VP of Healthcare and Life Sciences at DataArt, examines some of the ways these breakthroughs are transforming drug discovery

Opening the aperture: taking a wider view of the inhalables market

With a new company strategy in place and a combined focus on both drug and device development, Dr Kevin Robinson spoke to Vectura’s new CEO and Executive Director, Will Downie, about the current and future market for inhaled therapies

Rethinking HPLC degassing with novel flat film technology

During the first three decades of liquid chromatography (LC) use, outgassing in the mobile phase was a key challenge in routine LC workflows. However, since the emergence of online degassers in the 1970s, these devices have become an ordinary component of most LC systems and, therefore, their development is often overlooked

Expanding globally: building on a European presence

To build the overseas presence of Federal Equipment Company and solidify our status as a global provider of equipment solutions, we have opened an office in the Netherlands, reports Paul Sombekke, European Business Development Manager

Granulation: an established technology in a changing world

Optimising the granulation process — the most important unit operation during the production of pharmaceutical oral solid dosage forms — is not only a critical aspect of operational excellence, it also plays a major role in preventing downstream compression problems

John Baker: life sciences need to address the reproducibility crisis

The head of product innovation at Abcam says it is crucial that the whole industry finds ways to de-risk the route to the patient as early as possible

Optimise desiccants with 3D validation software

Baltimore's CFD model brings predictive science to validation. Desiccants are tested for performance over time, bringing cost-efficiency to the forefront. Dr Mark Valentine explains

IntelGenx: oral films are drug development’s patent trick

Exploiting improvements in bioavailability, the Canadian company has developed unique oral film technology to help drugmakers secure exclusivity and financial returns

How to avoid sticking and picking in the tableting industry

John Norman and Kevin Queensen of Natoli Engineering explain

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Performance validation: HPAPI containment testing in a risk-based era Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, thereby improving levels of containment performance
  3. Reading and understanding vendor-supplied tablet drawings Understanding the tablet drawings supplied by tooling vendors is a meaningful way to learn more about your product, reports John Norman, Technical Service Representative, Natoli Engineering Company
  4. Developing strategies for robust chemistry, manufacturing and controls execution for advanced biologics Chemistry, manufacturing and controls (CMC) is a fundamental discipline for complex drug development projects. It must be rigorously implemented to navigate stringent regulatory requirements before drug approval and commercialisation
  5. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin